Selective effects of CPAP on sleep apnoea-associated manifestations

Alexandros Vgontzas, E. Zoumakis, Edward Bixler, H. M. Lin, Belinda Collins, M. Basta, S. Pejovic, G. P. Chrousos

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: Visceral adiposity and obstructive sleep apnoea (OSA) may be independently associated with daytime sleepiness/low performance, insulin resistance, hypercytokinaemia, and/or hypertension. The objectives of this study are to simultaneously test these associations at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Materials and methods: Sixteen obese men with OSA; 13 non-apnoeic, obese controls, and 15 non-obese controls were monitored in the sleep laboratory for four consecutive nights. Objective measures of daytime sleepiness and performance, serial 24 h plasma measures of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), TNF receptor 1 (TNF-r1) and adiponectin, fasting blood glucose and insulin, visceral adiposity and blood pressure were obtained. Sleep apnoeics were re-assessed using the same protocol after 3 months of CPAP. Results: At baseline, IL-6, TNF-r1, and insulin resistance were highest in OSA patients, intermediate in obese controls, and lowest in non-obese controls (P < 0.05). Visceral fat was significantly greater in sleep apnoeics than obese controls and predicted insulin resistance and IL-6 levels, whereas OSA predicted TNF-r1 levels (P < 0.05). CPAP decreased daytime sleepiness and blood pressure (P < 0.05), but did not affect fasting glucose or insulin or around the clock adiponectin, IL-6, TNF-α, or TNF-r1 levels. Conclusions: In obese sleep apnoeics, visceral fat is strongly associated with insulin resistance and inflammation. CPAP decreases sleepiness and moderates hypertension but does not affect visceral adiposity, insulin resistance, hypoadiponectinaemia or hypercytokinaemia, all of which are independent risk factors for cardiovascular disease and diabetes.

Original languageEnglish (US)
Pages (from-to)585-595
Number of pages11
JournalEuropean Journal of Clinical Investigation
Volume38
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

Continuous Positive Airway Pressure
Sleep Apnea Syndromes
Insulin Resistance
Obstructive Sleep Apnea
Interleukin-6
Adiposity
Sleep
Tumor Necrosis Factor-alpha
Insulin
Intra-Abdominal Fat
Tumor Necrosis Factor Receptors
Adiponectin
Fasting
Blood pressure
Blood Pressure
Hypertension
Fats
Blood Glucose
Cardiovascular Diseases
Inflammation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry

Cite this

Vgontzas, Alexandros ; Zoumakis, E. ; Bixler, Edward ; Lin, H. M. ; Collins, Belinda ; Basta, M. ; Pejovic, S. ; Chrousos, G. P. / Selective effects of CPAP on sleep apnoea-associated manifestations. In: European Journal of Clinical Investigation. 2008 ; Vol. 38, No. 8. pp. 585-595.
@article{a825527bd4b3406c8f76a9fa1d05f256,
title = "Selective effects of CPAP on sleep apnoea-associated manifestations",
abstract = "Background: Visceral adiposity and obstructive sleep apnoea (OSA) may be independently associated with daytime sleepiness/low performance, insulin resistance, hypercytokinaemia, and/or hypertension. The objectives of this study are to simultaneously test these associations at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Materials and methods: Sixteen obese men with OSA; 13 non-apnoeic, obese controls, and 15 non-obese controls were monitored in the sleep laboratory for four consecutive nights. Objective measures of daytime sleepiness and performance, serial 24 h plasma measures of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), TNF receptor 1 (TNF-r1) and adiponectin, fasting blood glucose and insulin, visceral adiposity and blood pressure were obtained. Sleep apnoeics were re-assessed using the same protocol after 3 months of CPAP. Results: At baseline, IL-6, TNF-r1, and insulin resistance were highest in OSA patients, intermediate in obese controls, and lowest in non-obese controls (P < 0.05). Visceral fat was significantly greater in sleep apnoeics than obese controls and predicted insulin resistance and IL-6 levels, whereas OSA predicted TNF-r1 levels (P < 0.05). CPAP decreased daytime sleepiness and blood pressure (P < 0.05), but did not affect fasting glucose or insulin or around the clock adiponectin, IL-6, TNF-α, or TNF-r1 levels. Conclusions: In obese sleep apnoeics, visceral fat is strongly associated with insulin resistance and inflammation. CPAP decreases sleepiness and moderates hypertension but does not affect visceral adiposity, insulin resistance, hypoadiponectinaemia or hypercytokinaemia, all of which are independent risk factors for cardiovascular disease and diabetes.",
author = "Alexandros Vgontzas and E. Zoumakis and Edward Bixler and Lin, {H. M.} and Belinda Collins and M. Basta and S. Pejovic and Chrousos, {G. P.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1111/j.1365-2362.2008.01984.x",
language = "English (US)",
volume = "38",
pages = "585--595",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "8",

}

Selective effects of CPAP on sleep apnoea-associated manifestations. / Vgontzas, Alexandros; Zoumakis, E.; Bixler, Edward; Lin, H. M.; Collins, Belinda; Basta, M.; Pejovic, S.; Chrousos, G. P.

In: European Journal of Clinical Investigation, Vol. 38, No. 8, 01.08.2008, p. 585-595.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selective effects of CPAP on sleep apnoea-associated manifestations

AU - Vgontzas, Alexandros

AU - Zoumakis, E.

AU - Bixler, Edward

AU - Lin, H. M.

AU - Collins, Belinda

AU - Basta, M.

AU - Pejovic, S.

AU - Chrousos, G. P.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Background: Visceral adiposity and obstructive sleep apnoea (OSA) may be independently associated with daytime sleepiness/low performance, insulin resistance, hypercytokinaemia, and/or hypertension. The objectives of this study are to simultaneously test these associations at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Materials and methods: Sixteen obese men with OSA; 13 non-apnoeic, obese controls, and 15 non-obese controls were monitored in the sleep laboratory for four consecutive nights. Objective measures of daytime sleepiness and performance, serial 24 h plasma measures of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), TNF receptor 1 (TNF-r1) and adiponectin, fasting blood glucose and insulin, visceral adiposity and blood pressure were obtained. Sleep apnoeics were re-assessed using the same protocol after 3 months of CPAP. Results: At baseline, IL-6, TNF-r1, and insulin resistance were highest in OSA patients, intermediate in obese controls, and lowest in non-obese controls (P < 0.05). Visceral fat was significantly greater in sleep apnoeics than obese controls and predicted insulin resistance and IL-6 levels, whereas OSA predicted TNF-r1 levels (P < 0.05). CPAP decreased daytime sleepiness and blood pressure (P < 0.05), but did not affect fasting glucose or insulin or around the clock adiponectin, IL-6, TNF-α, or TNF-r1 levels. Conclusions: In obese sleep apnoeics, visceral fat is strongly associated with insulin resistance and inflammation. CPAP decreases sleepiness and moderates hypertension but does not affect visceral adiposity, insulin resistance, hypoadiponectinaemia or hypercytokinaemia, all of which are independent risk factors for cardiovascular disease and diabetes.

AB - Background: Visceral adiposity and obstructive sleep apnoea (OSA) may be independently associated with daytime sleepiness/low performance, insulin resistance, hypercytokinaemia, and/or hypertension. The objectives of this study are to simultaneously test these associations at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy. Materials and methods: Sixteen obese men with OSA; 13 non-apnoeic, obese controls, and 15 non-obese controls were monitored in the sleep laboratory for four consecutive nights. Objective measures of daytime sleepiness and performance, serial 24 h plasma measures of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), TNF receptor 1 (TNF-r1) and adiponectin, fasting blood glucose and insulin, visceral adiposity and blood pressure were obtained. Sleep apnoeics were re-assessed using the same protocol after 3 months of CPAP. Results: At baseline, IL-6, TNF-r1, and insulin resistance were highest in OSA patients, intermediate in obese controls, and lowest in non-obese controls (P < 0.05). Visceral fat was significantly greater in sleep apnoeics than obese controls and predicted insulin resistance and IL-6 levels, whereas OSA predicted TNF-r1 levels (P < 0.05). CPAP decreased daytime sleepiness and blood pressure (P < 0.05), but did not affect fasting glucose or insulin or around the clock adiponectin, IL-6, TNF-α, or TNF-r1 levels. Conclusions: In obese sleep apnoeics, visceral fat is strongly associated with insulin resistance and inflammation. CPAP decreases sleepiness and moderates hypertension but does not affect visceral adiposity, insulin resistance, hypoadiponectinaemia or hypercytokinaemia, all of which are independent risk factors for cardiovascular disease and diabetes.

UR - http://www.scopus.com/inward/record.url?scp=47649089967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649089967&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2008.01984.x

DO - 10.1111/j.1365-2362.2008.01984.x

M3 - Article

C2 - 18627419

AN - SCOPUS:47649089967

VL - 38

SP - 585

EP - 595

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 8

ER -